INSURANEWS Logo
Top Stories
Life
Health
Medicare
Property & Casualty
Annuity
Industry

Managing Healthcare Costs with HRAs and GLP-1 Medications

Share:

As healthcare costs rise, particularly those associated with GLP-1 weight-loss medications, U.S. employers are increasingly turning to health reimbursement arrangements (HRAs) to manage these expenses effectively.

The recent trend of shifting GLP-1 drugs to HRAs reflects an emergent strategy among employers to curb rising costs. Chris Byrd from WEX highlighted the financial advantages of this approach, noting the potential cost savings when these drugs are separated from regular employer drug plans. Utilizing HRAs, employers can take advantage of alternative purchasing channels—such as manufacturer support programs and platforms like GoodRx—that often offer more competitive prices than those negotiated by pharmacy benefit managers (PBMs).

Adjusting Coverage Approaches

Prominent companies like Starbucks are setting the standard by limiting GLP-1 drug coverage for non-medical use. This reflects a broader reevaluation by early adopters of inclusive GLP-1 coverage. Facing budget constraints, employers are now incorporating clinical criteria, such as a type 2 diabetes diagnosis or specific BMI thresholds, for coverage eligibility.

Despite the challenges, employer coverage of GLP-1s remains a hot topic. According to the Kaiser Family Foundation, around 18% of U.S. adults have tried GLP-1s, while 66% of employees believe these drugs should be covered by employers. This highlights the delicate balance employers must strike between employee expectations and financial realities.

The Role of HRAs in Cost Management

HRAs are proving instrumental in extending the value of employee benefits. As consumer-market prices increasingly undercut those set by PBMs, employers find an opportunity to contain costs through HRAs, which set a fixed monthly budget. This structure also encourages better employee adherence when net expenses are lower.

  • HRAs offer flexibility in structure.
  • Eligibility often requires participation in health coaching.
  • Alternatives include direct-to-consumer programs, reducing employer funding reliance.

Rick Kelly of Marsh McLennan Agency notes a notable decline in employers covering GLP-1s due to cost pressures. This points to HRAs becoming part of a broader move towards customizable benefits that complement foundational coverage.

Strategic Considerations for Brokers

Insurance brokers play a vital role in navigating the complexities of GLP-1 coverage. Byrd suggests brokers assist employers in scrutinizing existing coverage, evaluating attached lifestyle programs, and comparing consumer market prices with PBM rates. This can lead to informed decisions about carving out high-cost specialty drugs, aligning with industry trends and regulatory developments.

Additionally, Byrd highlights the increase in interest for individual coverage HRAs, especially among smaller employers aiming to simplify group health plan administration. This model allows the allocation of fixed amounts for employees to buy their insurance, offering flexibility and control.

Looking Ahead

The landscape for managing healthcare costs continues to evolve, supported by data transparency rules and artificial intelligence. These technological advancements enhance healthcare consumerism and bolster the role of benefits brokers as trusted advisors. As options multiply, clear communication becomes essential to ensure employees are well-informed about their benefits.